Chelsea Therapeutics International (CHTP) 6.52 $CHTP
29.6% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Tue Jul 29, 11:15AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 7 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
Chelsea Therapeutics International Has Returned 29.6% Since SmarTrend Recommendation (CHTP)
Comtex SmarTrend(R) - Tue Jul 22, 9:57AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 6 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
Chelsea Therapeutics International Shares Up 29.6% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Mon Jul 07, 5:42PM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 6 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
Lundbeck Completes Acquisition of Chelsea Therapeutics
Business Wire - Tue Jun 24, 9:00AM CDT
H. Lundbeck A/S (Lundbeck) today announced that it has completed its acquisition of Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) (Chelsea) for USD 6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional USD 1.50 per share upon achievement of certain sales milestones, in each case without interest and subject to any required withholding of taxes. As a result of the acquisition, Chelsea became a wholly-owned indirect subsidiary of Lundbeck, and shares of Chelsea common stock will no longer be listed on the NASDAQ Capital Market.
Downgrade Alert for Chelsea Therapeutics International (CHTP)
Comtex SmarTrend(R) - Tue Jun 24, 6:55AM CDT
Chelsea Therapeutics International (NASDAQ:CHTP) was downgraded from Outperform to Neutral at Wedbush today. The stock closed yesterday at $6.52 on volume of 6.1 million shares, above average daily volume of 6.1 million. Chelsea Therapeutics International Ltd. is a biopharmaceutical company developing a pipeline of low toxicity antifolate compounds engineered to have anti-inflammatory and anti-tumor activity. The Company's lead candidate is in development as a metabolically inert treatment alternative to Methotrexate for rheumatoid arthritis, psoriasis, and other disorders.
Shares of CHTP Up 31.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jun 23, 10:00AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 5 months, Chelsea Therapeutics International has returned 31.81% as of today's recent price of $6.63.
NORTHERA(TM) Clinical Trial Data Published in Neurology
GlobeNewswire - Thu Jun 19, 3:30PM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the publication in Neurology of its pivotal, Phase 3 study 301, a multicenter, multinational, double-blind, randomized, placebo-controlled, parallel-group study of NORTHERA (droxidopa) that details how NORTHERA demonstrated a statistically significant difference in efficacy compared to placebo for improving the symptoms of neurogenic orthostatic hypotension (NOH).
Upcoming Conferences, Tentative Meeting Schedules, Analyst Day, Public Offerings, and Data Presentations - Analyst Notes on Incyte, NPS Pharmaceuticals, Arrowhead, Novavax and Chelsea Therapeutics
PR Newswire - Tue Jun 17, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Arrowhead Research Corp. (NASDAQ: ARWR), Novavax, Inc. (NASDAQ: NVAX) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3787-100free.
Uptrend Call Working As Chelsea Therapeutics International Stock Rises 30.0% (CHTP)
Comtex SmarTrend(R) - Mon Jun 16, 9:24AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 5 months, Chelsea Therapeutics International has returned 30.02% as of today's recent price of $6.54.
Chelsea Therapeutics Presents Efficacy and Safety Data for NORTHERA at International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Thu Jun 12, 6:29AM CDT
-First Presentation of Integrated Data Analyses From Two Pivotal Trials
Chelsea Therapeutics International Shares Up 30.4% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Fri Jun 06, 5:33PM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 5 months, Chelsea Therapeutics International has returned 30.42% as of today's recent price of $6.56.
Chelsea Therapeutics Announces the Expiration of the Hart-Scott-Rodino Waiting Period in Relation to the Proposed Acquisition of Chelsea Therapeutics by Lundbeck
GlobeNewswire - Fri Jun 06, 6:00AM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act"
in connection with the previously announced Agreement and Plan of Merger, dated as of May 7, 2014 (the "Merger Agreement" , by and among Chelsea, H. Lundbeck A/S ("Lundbeck" , and Charlie Acquisition Corp., an indirect wholly owned subsidiary of Lundbeck ("Acquisition Sub" .
The Law Office of Robbins Arroyo LLP Announces Class Action Lawsuit Against Chelsea Therapeutics International, Ltd.
PR Newswire - Mon Jun 02, 2:32PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP announce that the firm filed a class action lawsuit on May 30, 2014, in the U.S. District Court for the District of Delaware (the "Court" , on behalf of the shareholders of Chelsea Therapeutics International, Ltd. ("Chelsea" (NASDAQ: CHTP) against Chelsea, its Board of Directors, for, among other things, violations of sections 14(e) and 20(a) of the U.S. Securities and Exchange Act of 1934 (the "Exchange Act" and U.S. Securities and Exchange Commission Rule 14a-9 promulgated thereunder.
Chelsea Therapeutics International Up 29.8% Since SmarTrend Uptrend Call (CHTP)
Comtex SmarTrend(R) - Fri May 30, 4:50PM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 5 months, Chelsea Therapeutics International has returned 29.82% as of today's recent price of $6.53.
Active Stocks Technical Coverage -- Research on Callaway Golf, Annaly Capital Management, Weatherford Intl., and Chelsea Therapeutics Intl.
PR Newswire - Wed May 21, 10:11AM CDT
The markets on Tuesday, May 20, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,374.31, down 0.83% and the NASDAQ Composite closed at 4,096.89, down 0.70%. The S&P 500 edged 0.65% lower, to finish the day at 1,872.83. The losses were broad based as nine out of ten sectors ended the session in negative. During the session, Consumer Discretionary, Industrials and Telecommunication Services sectors ended in negative, while some positive momentum was observed in the Utilities sector. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Callaway Golf Company (NYSE: ELY), Annaly Capital Management Inc. (NYSE: NLY), Weatherford International Ltd (NYSE: WFT) and Chelsea Therapeutics International Ltd (NASDAQ: CHTP). Free technical research on ELY, NLY, WFT and CHTP can be downloaded upon signing up at: http://www.investor-edge.com/2816-register
Chelsea Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate the Acquisition Proposal from H. Lundbeck A/S
Business Wire - Wed May 21, 9:58AM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Chelsea Therapeutics ("Chelsea" (NasdaqCM: CHTP) concerning the proposed acquisition by H. Lundbeck. Under the acquisition proposal, valued at approximately $658 million, Chelsea shareholders will only receive $6.44 in cash per share owned and contingent value rights worth up to $1.50. The total possible consideration of $7.94 is well below at least one analyst's estimated value of $12 per share.
29.6% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Tue Jul 29, 11:15AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 7 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
Chelsea Therapeutics International Has Returned 29.6% Since SmarTrend Recommendation (CHTP)
Comtex SmarTrend(R) - Tue Jul 22, 9:57AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 6 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
Chelsea Therapeutics International Shares Up 29.6% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Mon Jul 07, 5:42PM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 6 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
Lundbeck Completes Acquisition of Chelsea Therapeutics
Business Wire - Tue Jun 24, 9:00AM CDT
H. Lundbeck A/S (Lundbeck) today announced that it has completed its acquisition of Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) (Chelsea) for USD 6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional USD 1.50 per share upon achievement of certain sales milestones, in each case without interest and subject to any required withholding of taxes. As a result of the acquisition, Chelsea became a wholly-owned indirect subsidiary of Lundbeck, and shares of Chelsea common stock will no longer be listed on the NASDAQ Capital Market.
Downgrade Alert for Chelsea Therapeutics International (CHTP)
Comtex SmarTrend(R) - Tue Jun 24, 6:55AM CDT
Chelsea Therapeutics International (NASDAQ:CHTP) was downgraded from Outperform to Neutral at Wedbush today. The stock closed yesterday at $6.52 on volume of 6.1 million shares, above average daily volume of 6.1 million. Chelsea Therapeutics International Ltd. is a biopharmaceutical company developing a pipeline of low toxicity antifolate compounds engineered to have anti-inflammatory and anti-tumor activity. The Company's lead candidate is in development as a metabolically inert treatment alternative to Methotrexate for rheumatoid arthritis, psoriasis, and other disorders.
Shares of CHTP Up 31.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jun 23, 10:00AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 5 months, Chelsea Therapeutics International has returned 31.81% as of today's recent price of $6.63.
NORTHERA(TM) Clinical Trial Data Published in Neurology
GlobeNewswire - Thu Jun 19, 3:30PM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the publication in Neurology of its pivotal, Phase 3 study 301, a multicenter, multinational, double-blind, randomized, placebo-controlled, parallel-group study of NORTHERA (droxidopa) that details how NORTHERA demonstrated a statistically significant difference in efficacy compared to placebo for improving the symptoms of neurogenic orthostatic hypotension (NOH).
Upcoming Conferences, Tentative Meeting Schedules, Analyst Day, Public Offerings, and Data Presentations - Analyst Notes on Incyte, NPS Pharmaceuticals, Arrowhead, Novavax and Chelsea Therapeutics
PR Newswire - Tue Jun 17, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Arrowhead Research Corp. (NASDAQ: ARWR), Novavax, Inc. (NASDAQ: NVAX) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3787-100free.
Uptrend Call Working As Chelsea Therapeutics International Stock Rises 30.0% (CHTP)
Comtex SmarTrend(R) - Mon Jun 16, 9:24AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 5 months, Chelsea Therapeutics International has returned 30.02% as of today's recent price of $6.54.
Chelsea Therapeutics Presents Efficacy and Safety Data for NORTHERA at International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Thu Jun 12, 6:29AM CDT
-First Presentation of Integrated Data Analyses From Two Pivotal Trials
Chelsea Therapeutics International Shares Up 30.4% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Fri Jun 06, 5:33PM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 5 months, Chelsea Therapeutics International has returned 30.42% as of today's recent price of $6.56.
Chelsea Therapeutics Announces the Expiration of the Hart-Scott-Rodino Waiting Period in Relation to the Proposed Acquisition of Chelsea Therapeutics by Lundbeck
GlobeNewswire - Fri Jun 06, 6:00AM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act"
in connection with the previously announced Agreement and Plan of Merger, dated as of May 7, 2014 (the "Merger Agreement" , by and among Chelsea, H. Lundbeck A/S ("Lundbeck" , and Charlie Acquisition Corp., an indirect wholly owned subsidiary of Lundbeck ("Acquisition Sub" . The Law Office of Robbins Arroyo LLP Announces Class Action Lawsuit Against Chelsea Therapeutics International, Ltd.
PR Newswire - Mon Jun 02, 2:32PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP announce that the firm filed a class action lawsuit on May 30, 2014, in the U.S. District Court for the District of Delaware (the "Court"
, on behalf of the shareholders of Chelsea Therapeutics International, Ltd. ("Chelsea" (NASDAQ: CHTP) against Chelsea, its Board of Directors, for, among other things, violations of sections 14(e) and 20(a) of the U.S. Securities and Exchange Act of 1934 (the "Exchange Act" and U.S. Securities and Exchange Commission Rule 14a-9 promulgated thereunder. Chelsea Therapeutics International Up 29.8% Since SmarTrend Uptrend Call (CHTP)
Comtex SmarTrend(R) - Fri May 30, 4:50PM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 5 months, Chelsea Therapeutics International has returned 29.82% as of today's recent price of $6.53.
Active Stocks Technical Coverage -- Research on Callaway Golf, Annaly Capital Management, Weatherford Intl., and Chelsea Therapeutics Intl.
PR Newswire - Wed May 21, 10:11AM CDT
The markets on Tuesday, May 20, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,374.31, down 0.83% and the NASDAQ Composite closed at 4,096.89, down 0.70%. The S&P 500 edged 0.65% lower, to finish the day at 1,872.83. The losses were broad based as nine out of ten sectors ended the session in negative. During the session, Consumer Discretionary, Industrials and Telecommunication Services sectors ended in negative, while some positive momentum was observed in the Utilities sector. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Callaway Golf Company (NYSE: ELY), Annaly Capital Management Inc. (NYSE: NLY), Weatherford International Ltd (NYSE: WFT) and Chelsea Therapeutics International Ltd (NASDAQ: CHTP). Free technical research on ELY, NLY, WFT and CHTP can be downloaded upon signing up at: http://www.investor-edge.com/2816-register
Chelsea Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate the Acquisition Proposal from H. Lundbeck A/S
Business Wire - Wed May 21, 9:58AM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Chelsea Therapeutics ("Chelsea"
(NasdaqCM: CHTP) concerning the proposed acquisition by H. Lundbeck. Under the acquisition proposal, valued at approximately $658 million, Chelsea shareholders will only receive $6.44 in cash per share owned and contingent value rights worth up to $1.50. The total possible consideration of $7.94 is well below at least one analyst's estimated value of $12 per share. 
